Early aminotransferase improvement in the phase 2b NATIVE study is predictive of response pattern of liver histology as well as hepatic and cardiometabolic health markers at the end of treatment in patients with non-cirrhotic NASH

被引:0
|
作者
Anstee, Quentin [1 ]
Huot-Marchand, Philippe [2 ]
Dzen, Lucile [2 ]
Junien, Jean-Louis [2 ]
Broqua, Pierre [2 ]
Francque, Sven [3 ,5 ]
Abdelmalek, Manal [4 ]
Cooreman, Michael [2 ]
Harrison, Stephen
机构
[1] Newcastle Univ, Newcastle, NSW, Australia
[2] Inventiva Res & Dev, Daix, France
[3] Antwerp Univ Hosp, Edegem, Belgium
[4] Mayo Clin, Rochester, MN USA
[5] Univ Oxford, Oxford, England
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
SAT-393
引用
收藏
页码:S651 / S651
页数:1
相关论文
共 3 条
  • [1] THE PANPPAR AGONIST LANIFIBRANOR INDUCES BOTH RESOLUTION OF NASH AND REGRESSION OF FIBROSIS AFTER 24 WEEKS OF TREATMENT IN NON-CIRRHOTIC NASH: RESULTS OF THE NATIVE PHASE 2b TRIAL
    Francque, Sven M.
    Bedossa, Pierre
    Ratziu, Vlad
    Anstee, Quentin M.
    Bugianesi, Elisabetta
    Sanyal, Arun J.
    Loomba, Rohit
    Harrison, Stephen A.
    Balabanska, Rozalina Ivanova
    Mateva, Lyudmila
    Lanthier, Nicolas
    Alkhouri, Naim
    Moreno, Christophe
    Schattenberg, Jorn M.
    Stefanova-Petrova, Diana
    Vonghia, Luisa
    Rouzier, Regine
    Guillaume, Maeva
    Leroy, Vincent
    Romero-Gomez, Manuel
    Hodge, Alexander D.
    Huot-Marchand, Philippe
    Sabin, Nathalie
    Baudin, Martine
    Abitbol, Jean-Louis
    Broqua, Pierre
    Junien, Jean-Louis
    Abdelmalek, Manal F.
    HEPATOLOGY, 2020, 72 : 9A - 11A
  • [2] No MK-5172 Resistance Associated Variants (RAVs) identified in a vanguard cohort of treatment-naive, genotype 1, non-cirrhotic patients enrolled in the MK-5172 phase 2B study
    Barnard, Richard J.
    Howe, Anita Y.
    Strizki, Julie M.
    Hazuda, Daria
    Hwang, Peggy
    Gilbert, Christopher L.
    Mobashery, Niloufar
    Graham, Donald
    Newhard, William
    McHale, Carolyn M.
    HEPATOLOGY, 2012, 56 : 719A - 719A
  • [3] Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study
    Francque, Sven
    Cooreman, Michael
    Baudin, Martine
    Huot-Marchand, Philippe
    Dzen, Lucile
    Louis, Junien Jean
    Broqua, Pierre
    Abdelmalek, Manal
    JOURNAL OF HEPATOLOGY, 2021, 75 : S268 - S269